[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351859-105":59,"doc-detail-351859-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","case-report-converting-an-immunologically-cold-tumor-exceptional-response-to-cadonilimab-plus-chemotherapy-in-microsatellite-stable-pancreatic-cystadenocarcinoma","Case Report - Converting an immunologically \"cold\" tumor - exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma","","Pancreatic cancer remains largely refractory to immune checkpoint inhibitors, particularly the common microsatellite-stable (MSS) subtype. This case report describes an exceptional, durable response to cadonilimab, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy in a metastatic MSS pancreatic cystadenocarcinoma patient. Microsatellite stability was confirmed by immunohistochemistry and next-generation sequencing. After progression on first-line gemcitabine/nab-paclitaxel and TACE, the patient achieved near-complete remission within two months, later maintaining complete response for over 30 months after discontinuation due to grade 3 marrow suppression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/case-report-converting-an-immunologically-cold-tumor-exceptional-response-to-cadonilimab-plus-chemotherapy-in-microsatellite-stable-pancreatic-cystadenocarcinoma/351859/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/case-report-converting-an-immunologically-cold-tumor-exceptional-response-to-cadonilimab-plus-chemotherapy-in-microsatellite-stable-pancreatic-cystadenocarcinoma/351859.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are immune checkpoint inhibitors generally ineffective in microsatellite-stable pancreatic cancer?","Question",{"text":112,"@type":113},"Microsatellite-stable tumors often have an immunologically “cold” tumor microenvironment, characterized by low tumor mutational burden, low PD-L1 expression, and strong immunosuppression, which reduces responsiveness to PD-1/PD-L1 and CTLA-4 monotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was microsatellite stability determined in this case?",{"text":117,"@type":113},"Microsatellite stability was shown by immunohistochemistry with intact expression of MLH1, MSH2, MSH6, and PMS2, and confirmed by next-generation sequencing.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment led to the exceptional response?",{"text":121,"@type":113},"After progression on gemcitabine/nab-paclitaxel and transarterial chemoembolization, the patient received second-line cadonilimab combined with nab-paclitaxel and oxaliplatin, achieving near-complete remission by RECIST 1.1.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351859,1790156166,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":138,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":139,"faqs":140,"seo_title":141,"seo_description":67,"update_tm":142,"read_time":143,"preview_page_count":19,"preview_urls":144},4398046744996,"TYPE Case Report  \nPUBLISHED 29 May 2026  \nDOI 10.3389/fimmu.2026.1735785  \nOPEN ACCESS  \nEDITED BY  \nMing Yang,  \nUCONN Health, United States  \nREVIEWED BY  \nKuo-Hui Su,  \nThe University of Toledo, United States Prasanna Srinivasan Ramalingam, Vellore Institute of Technology, India  \n*CORRESPONDENCE  \nJiaju Xu  \n[jiajuxu1101@163.com](jiajuxu1101@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 30 October 2025  \nREVISED 09 April 2026  \nACCEPTED 19 May 2026  \nPUBLISHED 29 May 2026  \nCORRECTED 10 June 2026  \nCITATION  \nNi C, Xu J, Pang Y and Xu J (2026) Case Report: Converting an immunologically“cold” tumor: exceptional response tocadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma.  \nFront. Immunol. 17:1735785 .  \ndoi: 10.3389/fimmu.2026.1735785  \nCOPYRIGHT  \n© 2026 Ni, Xu, Pang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCase Report: Converting an immunologically “cold” tumor:  \nexceptional response tocadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma  \nChunxiao Ni 1†, Jiaju Xu 2†, Yu Pang 3 and Jiaju Xu 4*  \n1 Department of Minimally Invasive Oncology, Tai’an City Central Hospital, Tai ’an, Shandong, China, 2 Department of Pediatrics, Yantai Yuhuangding Hospital, Yantai, Shandong, China, 3 Department of Pathology, Tai’an City Central Hospital, Tai ’an, Shandong, China, 4 Department of Medical Oncology, Tai’an City Central Hospital, Tai’an, Shandong, China  \nBackground: Pancreatic cancer (PC) remains largely refractory to immune checkpoint inhibitors (ICIs), especially in the prevalent microsatellite-stable (MSS) subtype. However, combination strategies of ICIs with chemotherapy have largely failed in MSS PC, highlighting an urgent need for novel immunotherapeutic approaches. Cadonilimab is a novel programmed death protein 1(PD-1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) bispeciﬁc antibody designed toremodel the immunosuppressive tumor microenvironment.  \nCase report description: We report an exceptional and durable response tocadonilimab plus chemotherapy in a patient with metastatic MSS pancreatic cystade nocarcinoma (PCAC) . Microsatellite stability was shown by immunohistochemistry with intact expression of all four mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) and conﬁrmed by next-generation sequencing (NGS) . Following disease progression on ﬁrst-line gemcitabine/nabpaclitaxel and transarterial chemoembolization (TACE), the patient subsequently received second-line therapy with cadonilimab combined with nab-paclitaxeland oxaliplatin. Notably, within two months of treatment initiation, the patient achieved near-complete remission (near-CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, with an 89.9% reduction in the sum of target lesion diameters. Despite discontinuing anticancer therapy after 4 cycles due to grade 3 bone marrow suppression, which subsequently evolved into and has been maintained as a complete response (CR) for over 30 months, with the primary endpoint of progression-free survival (PFS) not yet reached.  \nConclusion: This case provides pioneering clinical evidence that cadonilimab, in combination with chemotherapy, can induce profound and durable remission in MSS PCAC, challenging current paradigms of ICI resistance and supporting the further development of bispeciﬁc antibody strategies.  \nKEYWORDS  \ncadonilimab, bispeciﬁc antibody, pancreatic cystadenocarcinoma, microsatellite stable, complete remission, immunotherapy  \nFrontiers in Immunology 01 [frontiersin.org](","cbCaingZSmNZ2EMJ","https://ap.wps.com/l/cbCaingZSmNZ2EMJ","pdf",2615189,"English","# Background\n# Case report description\n# Conclusion","[{\"question\":\"Why are immune checkpoint inhibitors generally ineffective in microsatellite-stable pancreatic cancer?\",\"answer\":\"Microsatellite-stable tumors often have an immunologically “cold” tumor microenvironment, characterized by low tumor mutational burden, low PD-L1 expression, and strong immunosuppression, which reduces responsiveness to PD-1/PD-L1 and CTLA-4 monotherapy.\"},{\"question\":\"How was microsatellite stability determined in this case?\",\"answer\":\"Microsatellite stability was shown by immunohistochemistry with intact expression of MLH1, MSH2, MSH6, and PMS2, and confirmed by next-generation sequencing.\"},{\"question\":\"What treatment led to the exceptional response?\",\"answer\":\"After progression on gemcitabine/nab-paclitaxel and transarterial chemoembolization, the patient received second-line cadonilimab combined with nab-paclitaxel and oxaliplatin, achieving near-complete remission by RECIST 1.1.\"}]","Case Report - Converting an immunologically \"cold\" tumor - exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma | PDF",1790096340,23,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2ea36fa079d0819e787550d6bc05c5c.webp",983,1389,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ac7f86b53cc774db6982b3c4c6c68b6.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ef3b455e8f2cd7050ce64c47ebb31e8.webp",981,1386,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b47a2547d51ad315fd922b8f56315ea1.webp",980,1385]